title: Expression of 14-3-3sigma, p16 and p53 proteins in anal squamous intraepithelial neoplasm and squamous cell carcinoma.
abstract: 14-3-3sigma is a p53-regulated G2/M inhibitor involved in numerous cellular signaling pathways related to cell cycle, DNA repair and apoptosis. Recent studies have showed that 14-3-3sigma was silenced transcriptionally through promoter hypermethylation mainly in HPV-negative vulvar squamous cell carcinoma (SCC). However, the expression of 14-3-3sigma protein has not yet been studied in anal SCC and its precursor, anal intraepithelial neoplasm (AIN). In this study, we evaluated the expression of 14-3-3sigma, p16 and p53 in 34 cases of normal perianal squamous mucosa, 5 cases of squamous hyperplasia and 62 cases of AIN, including 54 bowenoid and 8 differentiated AINs. Fourteen cases of invasive anal SCC were also included in the study, including 8 cases associated with bowenoid AIN and 6 cases associated with differentiated AIN. Expression of p16, p53 and 14-3-3sigma proteins was not seen in normal squamous epithelium. Weak staining for 14-3-3sigma was seen in anal squamous hyperplasia. Strong and diffuse p16 immunoreactivity was seen in 98.1% of bowenoid AIN, but only in 12.5% of differentiated AIN. In contrast, increased basal staining with suprabasal extension of p53 was seen in 100% of differentiated AIN, but in none of the bowenoid AIN. Expression of p16 and p53 was essentially mutually exclusive except in one case. Overexpression of 14-3-3sigma was detected in 97% (60/62) of AIN cases, including 96.3% of bowenoid AIN and 100% of differentiated AIN. Expression of 14-3-3sigma was independent of immunoreactivity status for p16 and p53. In conclusion, two histopathologic types of AIN, bowenoid and differentiated, have distinct immunoprofiles for p16 and p53, which suggests dual molecular pathways during anal carcinogenesis. Increased expression of 14-3-3sigma protein was found in approximately 97% of AIN lesions, regardless of histopathologic type and independent of p16 and p53 expression. Our study indicates that immunohistochemical detection of 14-3-3sigma in conjunction with p16 and p53 may be useful in histopathologic recognization of AIN.
authors.affiliation: Department of Anatomic Pathology, Cleveland Clinic Foundation Cleveland, Ohio, USA.
authors.forename: Andres A
authors.initials: AA
authors.lastname: Roma
authors.forename: John R
authors.initials: JR
authors.lastname: Goldblum
authors.forename: Victor
authors.initials: V
authors.lastname: Fazio
authors.forename: Bin
authors.initials: B
authors.lastname: Yang
references.citation: Clin Cancer Res. 2004 Apr 15;10(8):2687-93
references.pmid: 15102672
references.citation: Semin Cancer Biol. 2006 Jun;16(3):225-34
references.pmid: 16697215
references.citation: Histopathology. 2005 Jun;46(6):718-20
references.pmid: 15910611
references.citation: Semin Cancer Biol. 1998;8(5):345-57
references.pmid: 10101800
references.citation: Int J Gynecol Pathol. 2001 Jan;20(1):16-30
references.pmid: 11192069
references.citation: Semin Cancer Biol. 2006 Jun;16(3):161
references.pmid: 16697214
references.citation: Pathol Int. 2004 Oct;54(10):743-50
references.pmid: 15482563
references.citation: Nat Rev Cancer. 2003 Dec;3(12):931-43
references.pmid: 14737123
references.citation: Oncogene. 2002 Mar 14;21(12):1876-81
references.pmid: 11896620
references.citation: Oncogene. 2000 Nov 2;19(46):5298-302
references.pmid: 11077447
references.citation: Int J Gynecol Pathol. 2004 Jul;23(3):206-14
references.pmid: 15213596
references.citation: Anticancer Res. 2006 Jul-Aug;26(4B):3105-10
references.pmid: 16886641
references.citation: Cancer Res. 2000 Aug 15;60(16):4353-7
references.pmid: 10969776
references.citation: Mol Cell Proteomics. 2005 Jun;4(6):785-95
references.pmid: 15778465
references.citation: J Biol Chem. 2001 Nov 30;276(48):45193-200
references.pmid: 11577088
references.citation: Am J Surg Pathol. 2000 Mar;24(3):429-41
references.pmid: 10716158
references.citation: Am J Surg Pathol. 2006 Jul;30(7):795-801
references.pmid: 16819320
references.citation: Int J Oncol. 2004 Dec;25(6):1591-7
references.pmid: 15547695
references.citation: Proc Natl Acad Sci U S A. 2000 May 23;97(11):6049-54
references.pmid: 10811911
references.citation: Br J Cancer. 2004 Sep 13;91(6):1131-8
references.pmid: 15292943
references.citation: J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6
references.pmid: 7966400
references.citation: Br J Dermatol. 2007 Sep;157(3):523-30
references.pmid: 17573882
references.citation: J Low Genit Tract Dis. 2005 Apr;9(2):108-13
references.pmid: 15870532
references.citation: Semin Cancer Biol. 2006 Jun;16(3):183-92
references.pmid: 16697662
references.citation: J Low Genit Tract Dis. 2007 Jan;11(1):46-7
references.pmid: 17194951
references.citation: Cell Res. 2005 Apr;15(4):228-36
references.pmid: 15857577
references.citation: Hum Pathol. 2004 Dec;35(12):1477-83
references.pmid: 15619206
references.citation: Curr Opin Oncol. 2006 Sep;18(5):463-8
references.pmid: 16894294
references.citation: AIDS Read. 2005 Feb;15(2):79-82, 85-6, 88, 91
references.pmid: 15712398
references.citation: Mol Cell. 1997 Dec;1(1):3-11
references.pmid: 9659898
references.citation: Pathol Int. 2005 Feb;55(2):77-82
references.pmid: 15693853